2 registrations that name hydroxytyrosol as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 2 registrations
Status
Phase
1US sites across 1 state
1
2 to 4
5 to 19
20 or more
All 2 registrations
RecruitingNCT06833866
Phase I Trial of 5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) in Patients With Advanced or Metastatic Colorectal Cancer
Phase 1
The Methodist Hospital Research Institute
About 33 people
Started Dec 4, 2024
In plain words A Phase 1 study of hydroxytyrosol in people 18 and older, run by The Methodist Hospital Research Institute. It plans to enroll about 33 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Advanced or Metastatic CRC.
Male or female ≥18 years of age.
Histopathologically or cytologically confirmed advanced or metastatic CRC.
Patient who is eligible for first-line therapy for advanced or metastatic CRC, such as 5FU-based therapy.
Measurable disease per the RECIST v1.1.
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Hydroxytyrosol
Registered summary
This is a phase I study investigating the safety and antitumor activity of 5FU-based therapy (FOLFIRI/FOLFOX + Biologics) in combination with Hydroxytyrosol (HT) as a treatment for patients with advanced or metastatic colorectal cancer. Patients will receive: 1 capsule of HT 25 mg daily for 2 weeks before beginning 5FU-based therapy (FOLFIRI/FOLFOX + Biologics), 1 capsule of HT (25 mg) daily for 2 weeks while receiving the FOLFIRI/FOLFOX + Biologics, until sign of disease progression. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT07689214
Normast3 for Adults With Diabetic Polyneuropathy
No phase
University of Roma La Sapienza
About 40 people
Started Jul 17, 2024
In plain words A study of hydroxytyrosol in people 18 to 80, run by University of Roma La Sapienza. It plans to enroll about 40 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Diabete Type 2.
What it tests, as registered
Normast® 3 - a food for special medical purposes (FSMP) containing co-micronized palmitoylethanolamide (PEA) with rutin and hydroxytyrosol. It is designed to support the management of diabetic polyneu; Placebo
Registered summary
The goal of this clinical trial is to find out if a new supplement called Normast® 3 can help reduce nerve pain and improve nerve function in adults with diabetic polyneuropathy (DPN). DPN is a common complication of diabetes that damages nerves, often causing burning, tingling, or stabbing pain, as well as problems with the autonomic nervous system, which controls things like sweating and heart rate. The full summary is on the listing.